Manuel Figueroa, MD
General Practice · Los Angeles, CANPI 1770679102
Payments from drug & device makers
Across 71 payments — averaging $24.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$248
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$179
- Bayer$177
- Biotronik Inc.$138
- AbbVie$134
- Boehringer Ingelheim$125
- plus $717 from 16 others
What the payments were for
- Speaking & faculty fees$593%
- Food & beverage$1,63195%
- Education$272%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 9 | $248 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $179 |
| Bayer | 9 | $177 |
| Biotronik Inc. | 1 | $138 |
| AbbVie(2 entities) | 6 | $134 |
| Boehringer Ingelheim | 1 | $125 |
| Novo Nordisk | 5 | $98 |
| Amgen(2 entities) | 4 | $92 |
| Johnson & Johnson | 3 | $83 |
| AstraZeneca | 4 | $66 |
| Lilly USA, LLC | 3 | $56 |
| Astellas Pharma US Inc | 2 | $48 |
| GSK | 2 | $41 |
| Redhill Biopharma Inc. | 2 | $34 |
| Almatica Pharma LLC | 2 | $33 |
| Novartis | 2 | $33 |
| Amarin Pharma, Inc. | 2 | $32 |
| Calliditas Therapeutics US Inc. | 2 | $27 |
| Sumitomo Pharma America, Inc. | 1 | $26 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Radius Health, Inc. | 1 | $20 |
| Romark Laboratories, LC | 1 | $5 |
How this compares
$1,717 in reported general payments places this provider in the 85th percentile of 12,963 general practice providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KerendiaFinerenone | 124 | $105,294 |
| JanuviaSitagliptin Phosphate | 109 | $93,774 |
| FarxigaDapagliflozin Propanediol | 74 | $76,741 |
| EliquisApixaban | 54 | $51,981 |
| MyrbetriqMirabegron | 54 | $48,151 |
| GemtesaVibegron | 25 | $30,449 |
| TradjentaLinagliptin | 41 | $30,185 |
| OzempicSemaglutide | 27 | $29,417 |
| JardianceEmpagliflozin | 25 | $20,245 |
| TrulicityDulaglutide | 15 | $18,689 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 91 | $15,941 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $13,756 |
| Glipizide-MetforminGlipizide/Metformin Hcl | 104 | $12,238 |
| LinzessLinaclotide | 16 | $11,506 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 14 | $7,894 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerKerendia | $177 | $105,294124 claims |
| AstraZenecaFarxiga | $66 | $76,74174 claims |
| Boehringer IngelheimTradjenta, Jardiance, Combivent Respimat | $125 | $55,72377 claims |
| PfizerEliquis | $248 | $51,98154 claims |
| Astellas Pharma US IncMyrbetriq | $48 | $48,15154 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $26 | $30,44925 claims |
| Novo NordiskOzempic | $98 | $29,41727 claims |
| Lilly USA, LLCTrulicity | $56 | $18,68915 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $41 | $18,16034 claims |
| AbbVieLinzess | $134 | $11,50616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 12,963 general practice providers in California.
Other general practice in Los Angeles
- Bruce TorkanLos Angeles$3.8M
- Abdi SameniLos Angeles$316K
- Enrique GonzalezLos Angeles$303K
- Kent HwangLos Angeles$290K
- Kyle StanleyLos Angeles$259K
- Yang ChaiLos Angeles$150K
- Richard KimLos Angeles$97K
- Hessam AazamiCanoga Park$88.4M
- Frederic MollRedwood City$5.7M
- Nathan LiLancaster$5.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.